The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates,…
Read More
Pharma 50: The 50 Best-Selling Drugs of FY2025
The fiscal year 2025 concluded with a dramatic reshaping of the pharmaceutical industry’s top echelons, marked by intense competition at…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Eli Lilly Ascends to Pharma’s Top Revenue Spot Amidst Oral GLP-1 Approval, Yet Wall Street Remains Unconvinced.
Eli Lilly and Company, a venerable titan in the pharmaceutical industry, has achieved an unprecedented milestone, claiming the top spot…
Read More
New Qulipta Study Data Bolsters Case Against Restrictive European Reimbursement Policies
New clinical trial results presented by AbbVie are poised to significantly influence the landscape of migraine prevention in Europe, providing…
Read More
Biomarker Battles: Clinicians Champion Surrogate Endpoints Amidst Regulatory Caution
The complex interplay between clinical trial methodologies and regulatory approval pathways is currently being shaped by a vigorous debate surrounding…
Read More
Tavapadon Poised for Competitive Parkinson’s Disease Market Following Promising Tremor Data
AbbVie’s tavapadon, an investigational oral once-daily dopamine D1/D5 partial agonist, is nearing a potential regulatory submission, bolstered by new post-hoc…
Read More
OZMOSI and Planview Forge Strategic Alliance to Revolutionize Pharmaceutical R&D Planning with AI-Powered Clinical Intelligence
OZMOSI and Planview have announced a significant partnership aimed at transforming how pharmaceutical organizations approach research and development (R&D) planning.…
Read More
AI Governance and Trust: The Bedrock for Scaling Innovation in Drug Development
The accelerating adoption of artificial intelligence (AI) within the pharmaceutical industry is not merely a technological advancement; it is a…
Read More
Enanta Pharmaceuticals Poised to Lead Emerging RSV Therapeutics Market as Zelicapavir Advances to Phase III
Enanta Pharmaceuticals is strategically positioned to capture a significant share of the largely undeveloped market for respiratory syncytial virus (RSV)…
Read MoreYOU MAY HAVE MISSED
